For Pharma Marketers – a Christmas present

A solid group of experienced pharma marketing and e-healthcare folks contributed chapters to this e-book, called Best Strategic Learning Investment in 2010 (your investment: a bit of time – the download is free!) If you’re wondering how best to approach the on-line world of patient advocacy, communities, and social media, here’s your starting point. Contributors [...]

Read Full Post »

19 Seconds of Pure Joy

What happens when a 1-year old pup encounters her first serious snow of the season? Pure joy. For everyone. ———- Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news) Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample) Connect with Steve [...]

Read Full Post »

Impactiviti Daily 121809

This will be the final Impactiviti Daily for 2009. We’ll pick up again in the new year. Have a delightful holiday season! TODAY’S NEWS Deals – J&J and Merck get hits, Biogen strikes out. From PharmaExec – a new commercialization model needed for pharma? – The days when biopharmaceutical companies could rely upon a steady [...]

Read Full Post »

Impactiviti Daily 121609

TODAY’S NEWS Crestor – now no high cholesterol needed! Ah, lawyers. NJ, the judicial hellhole. And, the video Pfizer doesn’t want you to see. Rare diseases and big pharma. RECOMMENDED Compliance training. The Impactiviti network has great suppliers for all your corporate compliance needs.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) [...]

Read Full Post »

VaxTrak – a Novartis Goodie for the iPhone (review)

Along with many others, I’m of the opinion that the iPhone will prove to be a very powerful tool for health delivery. It’s a welcome sight to see pharma companies begin to experiment with it, and Novartis Vaccines has just released a nifty cool called VaxTrak (iTunes link), to help parents keep track of their [...]

Read Full Post »

Impactiviti Daily 121409

TODAY’S NEWS Sanofi – now laying off contract sales reps and some others. Pfizer and compliance. That’s a lot of corporate integrity agreements (from PharmaGossip blog) From the NYTimes: Menopause, as brought to you by Big Pharma – MILLIONS of American women in the 1990s were told they could help their bodies ward off major [...]

Read Full Post »

Impactiviti Daily 121109

TODAY’S NEWS Bone drugs may help prevent breast cancer? – New results from a landmark women’s health study raise the exciting possibility that bone-building drugs such as Fosamax and Actonel may help prevent breast cancer. Women who already were using these medicines when the study began were about one-third less likely to develop invasive breast [...]

Read Full Post »

Impactiviti Daily 121009

TODAY’S NEWS So…is Roche‘s Tamiflu really that effective? – The effectiveness of Roche Holding AG’s Tamiflu in treating flu complications in healthy adults can’t be determined because the Swiss drugmaker wouldn’t supply data from eight studies, an independent research group said…more The pharma layoff toll in 2009. Ugly. Pfizer to move into biosimilars? Not a [...]

Read Full Post »

Impactiviti Daily 120909

TODAY’S NEWS Novartis’ “son of Glivec” (Tasigna) carrying on the family tradition – Novartis has reported result of Tasigna Phase III clinical trial. In the study, Tasigna (nilotinib) demonstrated greater efficacy over Glivec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase…more Need to [...]

Read Full Post »

Impactiviti Daily 120809

TODAY’S NEWS Novartis gets FDA panel nod for transplant drug -  A U.S. advisory panel recommended approval of a Novartis AG drug to prevent rejection of transplanted kidneys, a Food and Drug Administration spokeswoman said on Monday. The panel voted 11-1 to urge FDA clearance of the drug, everolimus, for patients who have undergone kidney [...]

Read Full Post »